Efficacy of Neoadjuvant Targeted Therapy in Treatment of Patients with Localised Clear-Cell Renal Cell Carcinoma

Autor:	M. V. Pikul, I. Vitruk, O.A. Voylenko, S. L. Semko, O. A. Kononenko, O. E. Stakhovsky, E. O. Stakhovsky
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	medicine.medical_specialty Article Subject business.industry Urology medicine.medical_treatment 030232 urology & nephrology Obstetrics and Gynecology Cancer medicine.disease Diseases of the genitourinary system. Urology Confidence interval Nephrectomy Targeted therapy 03 medical and health sciences Clear cell renal cell carcinoma 0302 clinical medicine Renal cell carcinoma 030220 oncology & carcinogenesis Clinical endpoint Medicine RC870-923 Stage (cooking) business Research Article
Zdroj:	Advances in Urology Advances in Urology, Vol 2021 (2021)
ISSN:	1687-6369
DOI:	10.1155/2021/6674637
Popis:	Aim. This study aimed to evaluate the efficacy of neoadjuvant targeted therapy (TT) in patients with localised clear-cell renal cell carcinoma (RCC). Materials and Methods. A special randomised trial was planned and conducted by the Research Department of Plastic and Reconstructive Oncology in the National Cancer Institute of Ukraine for testing the clinical efficacy of neoadjuvant TT in the treatment of clear-cell localised RCC, and the primary endpoint was tumour response evaluation after TT. The secondary endpoints included evaluation of dependence between the use of neoadjuvant TT and the probability of partial nephrectomy and the correlation between tumour size, stage, remaining functioning parenchyma volume, and response to systemic therapy. Results. Overall, 118 patients met the inclusion criteria and were randomly assigned to receive combined treatment or surgery alone. The percentage of tumour regression ranged from 0% to 60%, and the median was (95% confidence interval) 20.5 ± 14.3 (16.8–24.3%). Most of the patients had a slightly positive response to TT (3%–29% decrease in tumour size); n = 44 (76.9%) cases. Partial response by the Response Evaluation Criteria in Solid Tumours, version 1.1, was observed in 14 (24.1%) patients and reached a maximum of 60% regression. Tumour reduction in the neoadjuvant TT group allowed kidney preservation in 53 (91.4%) patients. In the control group, the number of organ-sparing procedures was significantly lower (n = 20, 33.3%). The statistical difference was relevant (x2 = 42.1; p < 0.001 ). Conclusion. The positive results of neoadjuvant TT obtained in our study indicate the clinical validity of combined treatment in patients with localised RCC.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ce34facbd5e258b8ab419f2a813a1b Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.